Peregrine Ventures

Peregrine Ventures, established in 2001 and based in Or Yehuda, Israel, is a venture capital firm specializing in cross-stage investments. It primarily focuses on the Life Sciences, Digital Health, and Enterprise Software sectors, supporting promising companies with strategic investments and expert guidance throughout their lifecycle. Peregrine's approach extends beyond capital, offering deep industry knowledge and synergistic support to foster medical innovation and meaningful breakthroughs in healthcare.

David Eldar

CFO

Eyal Lifschitz

Co-Founder and Managing General Partner

Boaz Lifschitz

General Partner and Co - Founder

Eyal Lifshitz

Managing General Partner

94 past transactions

Lutris Pharma

Venture Round in 2025
Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, focused on developing innovative therapies to enhance the effectiveness of anti-cancer treatments. Established in 2015, the company has created a proprietary small molecule drug known as LUT014, which acts as a topical B-Raf inhibitor. This drug facilitates the use of epidermal growth factor receptor (EGFR) inhibitors while minimizing the common cutaneous side effects typically associated with such treatments. By addressing these side effects, Lutris Pharma aims to improve both the efficacy of anti-cancer therapies and the overall quality of life for patients undergoing treatment with EGFR inhibitors.

Variantyx

Series D in 2024
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

Bluewhite

Series C in 2024
Blue White Robotics is a company focused on revolutionizing agriculture through autonomy and innovative technology. It offers a comprehensive platform that enables the transformation of existing fleets into autonomous systems, effectively managing both aerial and ground robots. By utilizing remote sensing and artificial intelligence, the company collects and distributes data seamlessly, enhancing farm productivity and economics. Blue White Robotics aims to improve operational efficiency and safety while providing actionable insights that drive return on investment from the outset. Its solutions are designed to facilitate the easy and safe adoption of autonomous technology in agriculture, helping farmers build more resilient operations and reduce costs.

Variantyx

Venture Round in 2023
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

BioProtect

Venture Round in 2023
BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

Althea Medical

Pre Seed Round in 2023
Althea Medical is a medical device company based in Tel Aviv, Israel, founded in 2020. It focuses on developing innovative catheter devices specifically designed for the treatment of patients suffering from pulmonary embolism (PE), including both massive and sub-massive cases. The company's technology combines the effectiveness of large bore thrombectomy with a user-friendly delivery method that reduces patient risks. Their mechanical clot removal system is engineered to capture and eliminate thrombus bulk efficiently, allowing physicians to navigate quickly to obstructed areas and restore hemodynamic stability in affected patients.

DataMesh Group

Series A in 2023
DataMesh Group delivers integrated payment capabilities and valuable customer insights through bespoke payment and data processing solutions. The company offers financial payment systems software, infrastructure, and data analytics products. It enables retailers to design the customer experience they want to provide by providing the technology they want to deploy and creating a commerce and data hub that merchants, acquirers, card schemes, and third parties can use to achieve better business outcomes.

Nectin Therapeutics

Series A in 2022
Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Cordio

Venture Round in 2022
Cordio Medical LTD. is an innovative healthcare company based in Or Yehuda, Israel, founded in 2013. It specializes in developing a mobile application that leverages advanced speech processing technology to monitor patients with congestive heart failure. The platform enables near real-time monitoring and early detection of health deterioration through the analysis of patients' voice recordings. By transcribing patients' free speech into actionable insights, Cordio Medical assists healthcare providers in identifying and mitigating worsening conditions, ultimately aiming to prevent unnecessary hospitalizations and promote patient well-being. The company's approach integrates machine learning capabilities tailored to individual patients, enhancing the effectiveness of remote health monitoring and support.

Variantyx

Series C in 2022
Variantyx Inc. is a biotechnology company headquartered in Framingham, Massachusetts, that specializes in whole genome sequencing-based diagnostic testing. Founded in 2014, the company offers a comprehensive platform that includes its Genomic Unity® test, which identifies and reports all major types of genetic variants from a single patient sample. This test is designed to diagnose rare inherited disorders, providing a more efficient alternative to traditional genetic testing methods. Variantyx's technology enables hospitals and commercial laboratories to accurately analyze whole genome sequenced data, facilitating a better understanding of a patient's genetic makeup and leading to optimized treatment recommendations. The company's focus on genomic intelligence positions it at the forefront of precision medicine.

Bluewhite

Series B in 2021
Blue White Robotics is a company focused on revolutionizing agriculture through autonomy and innovative technology. It offers a comprehensive platform that enables the transformation of existing fleets into autonomous systems, effectively managing both aerial and ground robots. By utilizing remote sensing and artificial intelligence, the company collects and distributes data seamlessly, enhancing farm productivity and economics. Blue White Robotics aims to improve operational efficiency and safety while providing actionable insights that drive return on investment from the outset. Its solutions are designed to facilitate the easy and safe adoption of autonomous technology in agriculture, helping farmers build more resilient operations and reduce costs.

BrainQ

Venture Round in 2021
BrainQ is a company that specializes in developing precision neurology therapies aimed at treating impaired brain functions. Founded in 2016 and headquartered in Jerusalem, Israel, BrainQ utilizes a brain-computer interface (BCI)-based approach to target damaged neuronal networks and promote neuro recovery. By integrating machine learning algorithms with neuroscience, the company extracts biological insights that inform the creation of tailored therapies. This innovative approach aims to empower individuals with neurological disorders, helping them achieve greater independence and improved quality of life.

Aleph Farms

Series B in 2021
Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

Aleph Farms

Series B in 2021
Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

KAHR

Venture Round in 2021
KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Memic Innovative Surgery

Series D in 2021
Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

OutSense

Series A in 2020
OutSense is a company that develops an innovative IoT sensor aimed at early illness detection and wellness monitoring through the analysis of human waste. Their device utilizes advanced imaging technologies to detect trace amounts of blood in stool directly from a standard toilet bowl. By generating daily medical status reports based on biological excretions, OutSense enables caregivers to monitor essential health parameters and identify potential health issues. The primary focus of the company is to prevent colorectal cancer by providing a non-invasive screening method that alerts caregivers to deviations in health indicators. This approach offers a more efficient alternative to traditional stool sample testing, enhancing the ability to detect abnormal pathology and improve patient outcomes.

BioProtect

Series D in 2020
BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

Bluewhite

Series A in 2020
Blue White Robotics is a company focused on revolutionizing agriculture through autonomy and innovative technology. It offers a comprehensive platform that enables the transformation of existing fleets into autonomous systems, effectively managing both aerial and ground robots. By utilizing remote sensing and artificial intelligence, the company collects and distributes data seamlessly, enhancing farm productivity and economics. Blue White Robotics aims to improve operational efficiency and safety while providing actionable insights that drive return on investment from the outset. Its solutions are designed to facilitate the easy and safe adoption of autonomous technology in agriculture, helping farmers build more resilient operations and reduce costs.

Hairstetics

Convertible Note in 2020
Hairstetics Ltd. is a medical device company based in Omer, Israel, specializing in the development, manufacturing, and marketing of advanced hair restoration devices. Established in 2010, the company focuses on providing innovative solutions for hair loss, including both surgical hair transplantation and non-surgical options. Hairstetics offers a diverse range of hair implantations, allowing customers to choose from various colors, styles, and lengths. Their products are designed to simplify the implantation process, reduce recovery times, and deliver enhanced aesthetic outcomes at a more affordable price compared to traditional methods, thus catering to individuals seeking effective treatments for hair loss.

Levation Pharma

Venture Round in 2020
Levation Pharma is a company focused on the development of innovative dermatological solutions. It specializes in a topical oxymetazoline product intended for cosmetic eye lifts. This product is formulated as a drying aqueous gel that utilizes a transdermal delivery system of oxymetazoline. It aims to treat ptosis, or droopy upper eyelids, allowing patients to elevate their upper eyelids, thereby enhancing both their upper visual fields and the overall appearance of their eyes.

Artfix

Series A in 2020
Atrial Fibrillation treatment using cryo

Endomatic

Series A in 2020
Catheter procedure for LAA (left atrial appendage) closure, for Atrial fibrillation patients

Payzday

Series B in 2020
Payzday is a risk management solution provider based in Tel Aviv, Israel, that specializes in analyzing the risk levels of online merchants operating within marketplaces. Established in 2017, the company employs advanced technologies, including big data and artificial intelligence, to offer unprecedented visibility into merchant behavior. Payzday's approach goes beyond initial assessments during the onboarding process; it continuously monitors merchants in real-time, utilizing predictive analytics to identify potential unlawful or unstable situations. By providing financial institutions with detailed risk assessments, Payzday facilitates improved access to capital for online sellers, thereby enhancing their ability to secure necessary financing solutions.

SinuSafe Medical

Convertible Note in 2020
SinuSafe Medical is an innovative medical device company headquartered in Tel Aviv, Israel, founded in 2014. The company specializes in developing a nano-debrider device designed to address sinus-related issues without the need for surgical intervention. This device enables the irrigation and aspiration of the sinuses, providing a non-invasive solution for patients suffering from chronic sinusitis. By allowing sinus lavage to be performed in a physician's office, SinuSafe Medical aims to deliver immediate relief to ear, nose, and throat (ENT) patients, enhancing their overall treatment experience.

Restore Medical

Series A in 2020
Restore Medical is a medical device company based in Or Yehuda, Israel, established in 2016. The company specializes in providing innovative treatment solutions for patients suffering from congestive heart failure. Its flagship product, ContraBand, is a catheter-delivered implant designed specifically for patients with left ventricle failure who have preserved right ventricle function. This device aims to enhance left ventricle ejection fraction, minimize mitral regurgitation, and restore optimal ventricular geometry. By addressing these critical issues, Restore Medical's technology seeks to significantly improve patient quality of life and decrease rates of hospital readmission.

Raziel Health

Series C in 2019
Raziel Health, established in 2012 and headquartered in Rehovot, Israel, is a pharmaceutical company with a dual focus. Firstly, it develops injectable treatments, notably RZL-012, a novel synthetic small molecule designed to reduce fat tissue by causing fat cell death at the injection site. This drug is currently in clinical trials for various fat tissue indications and aesthetics. Secondly, Raziel Health offers a patient monitoring platform that uses artificial intelligence and machine learning to support remote patient care, enabling healthcare providers to improve patient outcomes across a wide range of conditions. The company's mission is to provide world-class, affordable healthcare in the comfort of patients' homes.

Raziel Health

Series C in 2019
Raziel Health, established in 2012 and headquartered in Rehovot, Israel, is a pharmaceutical company with a dual focus. Firstly, it develops injectable treatments, notably RZL-012, a novel synthetic small molecule designed to reduce fat tissue by causing fat cell death at the injection site. This drug is currently in clinical trials for various fat tissue indications and aesthetics. Secondly, Raziel Health offers a patient monitoring platform that uses artificial intelligence and machine learning to support remote patient care, enabling healthcare providers to improve patient outcomes across a wide range of conditions. The company's mission is to provide world-class, affordable healthcare in the comfort of patients' homes.

Magneto Thrombectomy Solutions

Series A in 2019
Magneto Thrombectomy Solutions is a medical device company focused on developing innovative thrombectomy devices for the treatment of ischemic stroke. Its technology enables the efficient and safe retrieval of various types of blood clots, ranging from large proximal to small distal clots. The device utilizes electric attractive forces that do not exert radial pressure on blood vessels, facilitating access to the most distal regions of the brain. This advancement allows medical professionals to effectively treat patients diagnosed with acute ischemic stroke who are candidates for thrombectomy, thereby aiming to optimize patient outcomes.

BioRefine

Seed Round in 2019
Medical device company treating the mitral valve

Roby.ai

Series A in 2019
Roby.ai is an innovative company that specializes in providing an artificial intelligence assistant tailored for rental agencies and property managers. Its platform automates a wide range of property management tasks, significantly reducing the need for human intervention and streamlining workflows. By utilizing push notifications through SMS and email, Roby.ai engages users and their clients throughout the rental process, enhancing communication and interaction. The technology alleviates the burden of mundane, time-consuming activities, allowing property managers to focus on more strategic aspects of their business. Ultimately, Roby.ai aims to improve operational efficiency, ensure compliance, and lower costs for its users, redefining how property management is conducted in a digital age.

Aleph Farms

Series A in 2019
Aleph Farms Limited is an innovative food technology company based in Ashdod, Israel, specializing in cellular agriculture to produce clean meat. Founded in 2017, Aleph Farms focuses on sustainable food production by developing methods to grow animal products directly from non-genetically modified animal cells, utilizing proprietary three-dimensional bioprinting technologies. The company made significant strides in the industry by unveiling the world's first cultivated thin-cut steak in 2018, followed by the first cultivated ribeye steak in 2021 and cultivated collagen in 2022. Under its product brand Aleph Cuts, its inaugural offering, the Petit Steak, is crafted from non-modified cells sourced from a premium Angus cow, allowing production without animal slaughter. Aleph Farms has garnered recognition for its commitment to climate leadership, including a net zero pledge made in 2020, earning accolades from prominent organizations like the World Economic Forum and the United Nations.

mPharma

Series B in 2019
mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.

Magnisity

Venture Round in 2019
Magnisity is a technology developer focused on creating innovative solutions for minimally invasive surgeries and medical devices. Established in 2018 in Or Yehuda, Israel, by Benny Greenburg and Ron Barak, the company specializes in using advanced algorithms to design hardware, develop software, and engineer precise mechanical systems. Magnisity's platform aims to assist surgeons and patients by addressing significant challenges in the field of endoluminal interventions, ultimately seeking to enhance the standards of surgical procedures.

Endomatic

Series A in 2018
Catheter procedure for LAA (left atrial appendage) closure, for Atrial fibrillation patients

Heracure

Seed Round in 2018
Heracure is a medical device company focused on advancing the treatment of uterine fibroids through innovative surgical techniques. The company specializes in the selective mechanical resection of fibroids using natural orifice access, specifically via the transvaginal route. Heracure is developing a cutting-edge control system designed to facilitate the safe removal of large uteri through this minimally invasive approach, providing healthcare professionals with effective alternatives to traditional abdominal surgery. By concentrating on improving surgical options, Heracure aims to enhance patient outcomes and expand the capabilities available to practitioners in the field of gynecological surgery.

Kymera Labs

Seed Round in 2018
Kymera Labs is a developer of synthetic data software that uses a novel algebra-based mathematical model to generate data while preserving the original statistical quality and characteristics. The company's innovative approach ensures that client data remains secure and compliant with privacy regulations. Kymera Labs' software allows for the synthesis of various data types, including scalars, labels, addresses, and dates, all while maintaining data dependencies and avoiding bias. This capability enhances the utility of synthetic data across different verticals, providing organizations with tailored solutions that meet their specific analytical needs.

Payzday

Seed Round in 2018
Payzday is a risk management solution provider based in Tel Aviv, Israel, that specializes in analyzing the risk levels of online merchants operating within marketplaces. Established in 2017, the company employs advanced technologies, including big data and artificial intelligence, to offer unprecedented visibility into merchant behavior. Payzday's approach goes beyond initial assessments during the onboarding process; it continuously monitors merchants in real-time, utilizing predictive analytics to identify potential unlawful or unstable situations. By providing financial institutions with detailed risk assessments, Payzday facilitates improved access to capital for online sellers, thereby enhancing their ability to secure necessary financing solutions.

Magneto Thrombectomy Solutions

Series A in 2018
Magneto Thrombectomy Solutions is a medical device company focused on developing innovative thrombectomy devices for the treatment of ischemic stroke. Its technology enables the efficient and safe retrieval of various types of blood clots, ranging from large proximal to small distal clots. The device utilizes electric attractive forces that do not exert radial pressure on blood vessels, facilitating access to the most distal regions of the brain. This advancement allows medical professionals to effectively treat patients diagnosed with acute ischemic stroke who are candidates for thrombectomy, thereby aiming to optimize patient outcomes.

Artfix

Seed Round in 2018
Atrial Fibrillation treatment using cryo

Restore Medical Solutions

Series A in 2018
Restore Medical Solutions, Inc., established in 2012 and based in Memphis, Tennessee, specializes in manufacturing modular sterilization tray systems for hospitals and surgery centers. Their products aim to reduce surgical site infections (SSIs), enhance safety, and improve productivity within the healthcare industry by minimizing the risk of contamination from medical instruments.

Memic Innovative Surgery

Series C in 2018
Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

Hairstetics

Seed Round in 2018
Hairstetics Ltd. is a medical device company based in Omer, Israel, specializing in the development, manufacturing, and marketing of advanced hair restoration devices. Established in 2010, the company focuses on providing innovative solutions for hair loss, including both surgical hair transplantation and non-surgical options. Hairstetics offers a diverse range of hair implantations, allowing customers to choose from various colors, styles, and lengths. Their products are designed to simplify the implantation process, reduce recovery times, and deliver enhanced aesthetic outcomes at a more affordable price compared to traditional methods, thus catering to individuals seeking effective treatments for hair loss.

Cliclap

Series A in 2018
CliClap Ltd., founded in 2016 and based in Kfar Saba, Israel, specializes in developing a content marketing utility for web browsers. This tool enhances audience engagement, brand awareness, and helps businesses achieve their goals by adding calls to action, scheduling posts, and analyzing success metrics. CliClap's AI-powered solution guides visitors through personalized content journeys, optimizing lead generation and qualification without manual management. The platform integrates seamlessly with existing marketing automation, CRM, social media management tools, and other systems, enabling more efficient marketing efforts and increasing conversion rates by at least 150%.

Cliclap

Seed Round in 2018
CliClap Ltd., founded in 2016 and based in Kfar Saba, Israel, specializes in developing a content marketing utility for web browsers. This tool enhances audience engagement, brand awareness, and helps businesses achieve their goals by adding calls to action, scheduling posts, and analyzing success metrics. CliClap's AI-powered solution guides visitors through personalized content journeys, optimizing lead generation and qualification without manual management. The platform integrates seamlessly with existing marketing automation, CRM, social media management tools, and other systems, enabling more efficient marketing efforts and increasing conversion rates by at least 150%.

DOKKA

Pre Seed Round in 2018
DOKKA is a cloud-based software company that specializes in automating the invoice processing workflow for accounting firms, bookkeepers, and small businesses. Utilizing proprietary artificial intelligence and visual recognition technology, DOKKA streamlines document classification and data capture, significantly reducing the time and costs associated with manual bookkeeping tasks. The platform seamlessly integrates with a wide range of accounting systems, including major ERP platforms, allowing for two-way data flow and easy deployment. DOKKA's solution is designed to alleviate bottlenecks in the accounting process, enabling users to focus on more strategic aspects of their work while minimizing errors typically associated with manual data entry. The implementation of DOKKA's technology can be completed in just 7 to 14 days, making it an efficient choice for businesses seeking to enhance their accounting operations.

Levation Pharma

Seed Round in 2018
Levation Pharma is a company focused on the development of innovative dermatological solutions. It specializes in a topical oxymetazoline product intended for cosmetic eye lifts. This product is formulated as a drying aqueous gel that utilizes a transdermal delivery system of oxymetazoline. It aims to treat ptosis, or droopy upper eyelids, allowing patients to elevate their upper eyelids, thereby enhancing both their upper visual fields and the overall appearance of their eyes.

Payzday

Seed Round in 2017
Payzday is a risk management solution provider based in Tel Aviv, Israel, that specializes in analyzing the risk levels of online merchants operating within marketplaces. Established in 2017, the company employs advanced technologies, including big data and artificial intelligence, to offer unprecedented visibility into merchant behavior. Payzday's approach goes beyond initial assessments during the onboarding process; it continuously monitors merchants in real-time, utilizing predictive analytics to identify potential unlawful or unstable situations. By providing financial institutions with detailed risk assessments, Payzday facilitates improved access to capital for online sellers, thereby enhancing their ability to secure necessary financing solutions.

Cordio

Series B in 2017
Cordio Medical LTD. is an innovative healthcare company based in Or Yehuda, Israel, founded in 2013. It specializes in developing a mobile application that leverages advanced speech processing technology to monitor patients with congestive heart failure. The platform enables near real-time monitoring and early detection of health deterioration through the analysis of patients' voice recordings. By transcribing patients' free speech into actionable insights, Cordio Medical assists healthcare providers in identifying and mitigating worsening conditions, ultimately aiming to prevent unnecessary hospitalizations and promote patient well-being. The company's approach integrates machine learning capabilities tailored to individual patients, enhancing the effectiveness of remote health monitoring and support.

Cordio

Series A in 2017
Cordio Medical LTD. is an innovative healthcare company based in Or Yehuda, Israel, founded in 2013. It specializes in developing a mobile application that leverages advanced speech processing technology to monitor patients with congestive heart failure. The platform enables near real-time monitoring and early detection of health deterioration through the analysis of patients' voice recordings. By transcribing patients' free speech into actionable insights, Cordio Medical assists healthcare providers in identifying and mitigating worsening conditions, ultimately aiming to prevent unnecessary hospitalizations and promote patient well-being. The company's approach integrates machine learning capabilities tailored to individual patients, enhancing the effectiveness of remote health monitoring and support.

Digma Medical

Series B in 2016
Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

Rise.ai

Seed Round in 2016
Rise.ai is a strategic re-engagement solution that offers brands and retailers a proprietary currency system designed to enhance customer retention and increase average spending. Utilizing artificial intelligence, the company operates a social gifting platform that facilitates gift card and store credit alternatives. Its platform effectively manages the entire re-engagement cycle, encompassing gift cards, loyalty cards, rewards, and refunds. Additionally, it enables users to send gifts such as drinks, coffee, and cakes to friends, thereby enhancing customer interaction. Through its innovative approach, Rise.ai assists eCommerce agencies, brands, and merchants in building stronger customer relationships and driving revenue growth.

Eve Pharma

Seed Round in 2016
Eve Pharma is a preclinical drug delivery company specializing in gynecology, focused on developing treatments for bacterial vaginosis. The firm aims to provide innovative solutions that enable clinicians to accurately identify the source of vaginal infections, facilitating easier diagnosis and treatment for patients. Through its lead product, Eve Pharma seeks to enhance the management of bacterial vaginosis, addressing a significant healthcare need in women's health.

OutSense

Seed Round in 2016
OutSense is a company that develops an innovative IoT sensor aimed at early illness detection and wellness monitoring through the analysis of human waste. Their device utilizes advanced imaging technologies to detect trace amounts of blood in stool directly from a standard toilet bowl. By generating daily medical status reports based on biological excretions, OutSense enables caregivers to monitor essential health parameters and identify potential health issues. The primary focus of the company is to prevent colorectal cancer by providing a non-invasive screening method that alerts caregivers to deviations in health indicators. This approach offers a more efficient alternative to traditional stool sample testing, enhancing the ability to detect abnormal pathology and improve patient outcomes.

Magneto Thrombectomy Solutions

Seed Round in 2016
Magneto Thrombectomy Solutions is a medical device company focused on developing innovative thrombectomy devices for the treatment of ischemic stroke. Its technology enables the efficient and safe retrieval of various types of blood clots, ranging from large proximal to small distal clots. The device utilizes electric attractive forces that do not exert radial pressure on blood vessels, facilitating access to the most distal regions of the brain. This advancement allows medical professionals to effectively treat patients diagnosed with acute ischemic stroke who are candidates for thrombectomy, thereby aiming to optimize patient outcomes.

NeuroApplied

Seed Round in 2016
NeuroApplied Ltd., founded in June 2016 and based in Hadera, Israel, specializes in customer-focused market research services that leverage the study of the collective subconscious. The company utilizes a SaaS-based platform that incorporates machine learning and neural network computing to analyze data collected through online picture games. This innovative approach allows NeuroApplied to provide valuable insights into subconscious brand perception, enabling brand managers to assess brand equity, track brand properties, and manage crises effectively. The platform features an intuitive dashboard that offers a nonintrusive and visually engaging experience for respondents, facilitating the collection of data that reflects customers' true thoughts and feelings.

Eximo

Series C in 2016
Eximo Medical Ltd. is an innovative company based in Modi'in-Maccabim-Re'ut, Israel, specializing in hybrid catheter technology for tissue resection in vascular and gastrointestinal endoluminal applications. Founded in 2012, Eximo has developed a proprietary single-use hybrid catheter known as CatHI, which integrates optical fibers that emit short laser pulses and a blunt mechanical knife. This advanced technology aims to enhance safety and performance during medical procedures, particularly in atherectomy, by minimizing the risk of vessel perforation. As of October 2019, Eximo Medical operates as a subsidiary of AngioDynamics, Inc.

Restore Medical Solutions

Seed Round in 2016
Restore Medical Solutions, Inc., established in 2012 and based in Memphis, Tennessee, specializes in manufacturing modular sterilization tray systems for hospitals and surgery centers. Their products aim to reduce surgical site infections (SSIs), enhance safety, and improve productivity within the healthcare industry by minimizing the risk of contamination from medical instruments.

mPharma

Seed Round in 2016
mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.

SinuSafe Medical

Seed Round in 2016
SinuSafe Medical is an innovative medical device company headquartered in Tel Aviv, Israel, founded in 2014. The company specializes in developing a nano-debrider device designed to address sinus-related issues without the need for surgical intervention. This device enables the irrigation and aspiration of the sinuses, providing a non-invasive solution for patients suffering from chronic sinusitis. By allowing sinus lavage to be performed in a physician's office, SinuSafe Medical aims to deliver immediate relief to ear, nose, and throat (ENT) patients, enhancing their overall treatment experience.

mPharma

Seed Round in 2016
mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.

Memic Innovative Surgery

Series A in 2015
Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

Memic Innovative Surgery

Seed Round in 2015
Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

Evolero

Seed Round in 2015
Evolero Ltd. is a company that specializes in providing event management software solutions tailored for event organizers and meeting planners. Founded in 2011 and based in Herzliya, Israel, Evolero offers a comprehensive platform that streamlines the process of conference planning and organization. Its software encompasses a range of online services, enabling users to sell tickets, manage event ticketing and registration, and equip sponsors with advanced marketing tools. Additionally, the platform enhances attendee experience by incorporating powerful networking features. Evolero positions itself as a one-stop solution for those involved in event management, facilitating both the logistical and promotional aspects of organizing conferences.

Cordio

Seed Round in 2014
Cordio Medical LTD. is an innovative healthcare company based in Or Yehuda, Israel, founded in 2013. It specializes in developing a mobile application that leverages advanced speech processing technology to monitor patients with congestive heart failure. The platform enables near real-time monitoring and early detection of health deterioration through the analysis of patients' voice recordings. By transcribing patients' free speech into actionable insights, Cordio Medical assists healthcare providers in identifying and mitigating worsening conditions, ultimately aiming to prevent unnecessary hospitalizations and promote patient well-being. The company's approach integrates machine learning capabilities tailored to individual patients, enhancing the effectiveness of remote health monitoring and support.

Yotta Green

Seed Round in 2014
Yotta Green is an innovative company that offers a smart home system designed to enhance energy efficiency and comfort while providing safety services tailored to household behavior. Utilizing proprietary technologies, Yotta's system monitors and measures household power consumption, learning consumer usage patterns over time. This capability allows the system to identify abnormal electrical behavior and provide valuable insights, such as alerting users to potential energy waste or electrical hazards, including fires. The system is equipped to take proactive measures, such as turning off unused lights and appliances or lowering blinds in anticipation of a storm. Yotta Green's services are accessible through a user-friendly smartphone app, as well as touch and gesture activation devices, ensuring convenience and ease of use for consumers.

ShapeDo

Pre Seed Round in 2014
ShapeDo Ltd. is a software development company based in Modi'in-Maccabim-Re'ut, Israel, founded in 2014. The company specializes in managing the implications of plan changes in construction projects through its cloud-based platform. ShapeDo's software facilitates comprehensive management of design changes, ensuring that all alterations are accurately reflected in contracts, budgets, and agreements. It provides functionalities such as blueprint version tracking, version comparison, and the generation of court-ready pricing reports, requests for information (RFIs), and claims. ShapeDo has been involved in significant infrastructure projects, including international airports, underground train systems, hospitals, and data centers, while also catering to smaller commercial and residential endeavors. Its solutions empower clients to navigate the complexities of design modifications and make necessary operational and financial adjustments seamlessly.

Jobrain

Seed Round in 2013
Jobrain Ltd. is a cloud-based hiring software provider based in Herzliya, Israel, designed to streamline the recruitment process for HR professionals and candidates. The platform enables candidates to apply for jobs easily while assisting HR teams in quickly identifying and hiring suitable talent. Jobrain features an open marketplace that offers a range of talent acquisition services, including job post distribution, remote and one-way video interviews, and candidate assessments. The company caters to head-hunters, agencies, and various hiring services, facilitating access to over 100,000 job positions, primarily in software development and startups. By leveraging data science, Jobrain simplifies the hiring process through a single interface, allowing clients to focus on essential tasks while minimizing administrative burdens.

Nitinotes

Seed Round in 2013
Nitinotes is a medical technology company specializing in minimally invasive gastrointestinal solutions. The company has introduced the EndoZip™, an automated gastroscopic suturing system designed for gastroenterologists and surgeons. This innovative system allows for safer and simpler gastrointestinal suturing, facilitating a non-surgical approach to bariatric treatment. By mimicking laparoscopic sleeve gastrectomy, the EndoZip™ enables effective weight-loss procedures for patients classified as obese class I and II, particularly those for whom traditional bariatric surgery is not suitable. Nitinotes aims to provide a widely accessible solution for endoscopic weight-loss treatments, ultimately helping patients achieve better health outcomes through advanced medical technology.

Zuznow

Seed Round in 2013
Zuznow is an Israeli company founded in 2009 that specializes in mobile adaptation solutions for websites. Its platform automates the analysis of a website's visual structure and adapts it for optimal viewing on smartphones, facilitating a seamless mobile experience. Zuznow's technology serves a diverse clientele, including notable companies such as VentureBeat, HOOP, Newsgeek, and BAKER TILLY. The platform offers rapid mobile application development capabilities, allowing businesses to efficiently create secure mobile applications from complex web structures. This comprehensive solution supports various enterprise applications, including B2B, B2C, and B2E, effectively reducing development time and costs by over 90%. Zuznow positions itself as a key resource for organizations looking to implement a sustainable mobile strategy in response to the increasing demand for mobile-friendly solutions.

MarketYze

Seed Round in 2012
Marketyze is a technology company specializing in e-commerce market intelligence for the retail industry. Founded in December 2011 in Israel by Onn Manelson and Nave Ronen, the company provides a cloud-based platform that offers semantic site search and online price comparison solutions. Its pricing intelligence software tracks and analyzes competitor pricing, market trends, and internal data, enabling retailers to understand the impact of pricing events on sales performance. By leveraging this information, companies can refine their pricing strategies to enhance both sales and profitability.

Evolero

Seed Round in 2012
Evolero Ltd. is a company that specializes in providing event management software solutions tailored for event organizers and meeting planners. Founded in 2011 and based in Herzliya, Israel, Evolero offers a comprehensive platform that streamlines the process of conference planning and organization. Its software encompasses a range of online services, enabling users to sell tickets, manage event ticketing and registration, and equip sponsors with advanced marketing tools. Additionally, the platform enhances attendee experience by incorporating powerful networking features. Evolero positions itself as a one-stop solution for those involved in event management, facilitating both the logistical and promotional aspects of organizing conferences.

NLT Spine

Venture Round in 2012
NLT Spine is a clinical stage company focused on developing and marketing innovative products for Minimally Invasive Spinal Surgery (MISS), aimed at treating degenerative spinal conditions. By utilizing non-linear technology, NLT Spine creates instruments and implants specifically designed for lumbar interbody fusion procedures and other surgical treatments of back pain. The company is dedicated to enhancing patient care by transitioning from traditional open surgical methods to more advanced, minimally invasive techniques that improve safety, predictability, and clinical outcomes.

ArTack Medical

Seed Round in 2012
ArTack Medical is a privately held medical device company based in Haifa, Israel, established in 2013. The company focuses on developing innovative tools for the invasive surgery market, particularly through its patented drive platform that enables the delivery of torque via a 5mm shaft. ArTack Medical's key product is an articulated hernia mesh fixation device designed to facilitate both laparoscopic and open surgical repairs. This device is compatible with any currently available mesh and allows surgeons to maintain their standard surgical techniques, thus enhancing operational efficiency without necessitating changes to established procedures.

Mend

Seed Round in 2011
Mend specializes in open-source software (OSS) lifecycle management solutions, offering a comprehensive cloud-based platform designed to manage the OSS lifecycle effectively. Their flagship product integrates seamlessly with development environments and DevOps pipelines, enabling real-time detection of open-source libraries that may pose security or compliance risks. Mend provides actionable remediation paths to resolve identified issues quickly and enforces automated policies to streamline the fixing process. The platform supports over 200 programming languages and continuously monitors multiple open-source vulnerability databases, ensuring that users are informed of potential risks while minimizing false positives. Founded in 2011 and headquartered in New York, Mend maintains additional offices in Boston, Givatayim, the United Kingdom, and Switzerland.

CartiHeal

Series C in 2011
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Peak-Dynamics

Seed Round in 2011
Peak-Dynamics is a research-driven technology company specializing in water utility management. It has developed PeakWater, an innovative software platform that enhances the efficiency of water delivery while minimizing energy costs. By integrating its Optimized Stochastic Search Algorithm, PeakWater monitors and controls the energy efficiency of water networks, interfacing with existing SCADA systems to gather real-time data. A distinctive feature of PeakWater is its comparative analysis of energy supplier tariffs, which empowers water authorities to navigate the open energy market effectively, ensuring compliance with contractual requirements while achieving significant cost savings. Marketed to water system management companies, integrators, and various governmental water authorities, Peak-Dynamics aims to elevate operational standards in the water-energy nexus. The company boasts a highly skilled team, including software developers, entrepreneurs, and experts in water system modeling and pricing decisions. With recent expansion efforts, including establishing a presence in the US, Peak-Dynamics is well-positioned for growth and innovation in water utility operations.

CardioGard Medical

Seed Round in 2011
CardioGard develops a specially designed arterial cannula for the removal of gaseous material during heart bypass surgeries. The system is composed of a double-lumen cannula in which the primary lumen provides oxygenated blood from the heart-lung machine to the patient and a secondary lumen suctions blood and embolic matter away from the surgical field and back to the cardiopulmonary bypass machine for the filtration.

Eximo

Seed Round in 2011
Eximo Medical Ltd. is an innovative company based in Modi'in-Maccabim-Re'ut, Israel, specializing in hybrid catheter technology for tissue resection in vascular and gastrointestinal endoluminal applications. Founded in 2012, Eximo has developed a proprietary single-use hybrid catheter known as CatHI, which integrates optical fibers that emit short laser pulses and a blunt mechanical knife. This advanced technology aims to enhance safety and performance during medical procedures, particularly in atherectomy, by minimizing the risk of vessel perforation. As of October 2019, Eximo Medical operates as a subsidiary of AngioDynamics, Inc.

Otic Pharma

Seed Round in 2010
Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

Valire

Seed Round in 2010
Valire is a software solution company based in HaMerkaz, Israel, founded in 2009, that specializes in artificial intelligence applications for fraud detection and risk assessment. The company focuses on developing innovative software that protects businesses' assets and reputations by identifying fraudulent behavior through a combination of business rules and symbolic machine learning. Valire's technology aims to minimize false positives and presents a cost-effective implementation, helping organizations reduce operational risks while optimizing their performance and growth opportunities.

Rocketick

Seed Round in 2010
Rocketick Technologies, established in 2008 and headquartered in Ramat Gan, Israel, specializes in GPU-based simulation acceleration solutions for chip verification. The company's flagship product, RocketSim, enhances functional verification processes by integrating GPU-based acceleration with existing simulators, enabling 10x faster simulations for complex designs. This solution is currently employed by several semiconductor customers, helping to reduce time to market for new chip designs. As of 2016, Rocketick operates as a subsidiary of Cadence Design Systems Inc.

QuickLizard

Seed Round in 2010
QuickLizard is an AI-driven technology provider specializing in dynamic pricing solutions for retailers and direct-to-consumer brands. The company offers a comprehensive platform that enables businesses to effectively manage their pricing strategies by utilizing advanced tools, insights, and analytics. QuickLizard's multi-channel platform supports a wide range of retail sectors, including consumer electronics, beauty, home furnishings, sporting goods, apparel, pet supplies, groceries, and airlines. Deployed in over 40 markets, the platform seamlessly integrates online and offline sales channels, generating hundreds of millions of pricing recommendations each month, thereby facilitating business expansion and enhancing profitability.

CartiHeal

Series A in 2009
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Cellvine

Seed Round in 2008
Cellvine is a company that specializes in developing and marketing advanced coverage and capacity solutions for the wireless telecommunications industry. It offers a wide array of cellular coverage enhancement products, leveraging its proprietary technology to improve cellular signals across various environments. These include in-building spaces, urban areas, rural settings, and challenging subterranean locations such as mines and tunnels. By focusing on innovative wireless communication technologies, Cellvine aims to enhance connectivity and performance for cellular networks.

CardioNova

Seed Round in 2007
CardioNova is a biotechnology company focused on developing medical solutions for cardiovascular diseases. The company specializes in innovative drugs designed to treat conditions such as atrial fibrillation and dyslipidemia, with the aim of preventing atherosclerosis. Its lead product, AHRO-001, represents a significant advancement in the treatment of these cardiovascular issues, allowing for rapid and cost-effective achievement of clinical objectives. Through its research and development efforts, CardioNova is committed to improving patient outcomes in the field of cardiovascular health.

Valtech Cardio

Seed Round in 2007
Valtech Cardio Ltd. is a medical device company based in Or Yehuda, Israel, founded in 2006. It specializes in the development and manufacturing of cardiovascular devices aimed at treating mitral and tricuspid valve regurgitation through minimally invasive techniques. The company’s flagship products include the Cardioband System, which reconstructs the mitral valve via transfemoral direct annuloplasty, and the Cardiovalve system, designed for transfemoral transseptal mitral valve replacement. Additionally, Valtech offers the Cardinal, an adjustable annuloplasty ring that allows surgeons to optimize valve repair during surgery. The company is also advancing its pipeline with products like Cardioband Tricuspid, aimed at mitral regurgitation treatment, and the V-Chordal, which addresses mitral valve prolapse. Valtech Cardio operates as a subsidiary of Zeppelin Zox Ltd.

Kailight Photonics

Series B in 2006
Kailight Photonics develops optical modules for the telecommunications industry. It offers tunable optical signal regenerator, an optical component that operates with regenerators, optical switches, add/drop multiplexers, and cross-connects. The company's optical transmission, signal regeneration, and wavelength conversion technology provides optical-networking solutions for systems vendors. It provides its products to long-haul network market segments. The company, formerly known as Chilight Technologies, was founded in 2000 and is headquartered in Rehovot, Israel with an additional office in Dallas, Texas. As of May 15, 2007, Kailight Photonics, Inc. operates as a subsidiary of Optium Corporation.

Neovasc

Seed Round in 2006
Neovasc Inc., a specialty medical device company headquartered in Richmond, Canada, develops, manufactures, and markets products for the cardiovascular marketplace globally. Its portfolio includes the Tiara technology, designed for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer, which treats refractory angina. The Reducer has been commercially available in Europe since 2015 but is not yet approved in the United States. Additionally, Neovasc offers pericardial tissue processing and vascular product development services to industry partners.

Topspin Medical

Series B in 2002
TopSpin Medical has developed a groundbreaking technology for high-resolution MRI imaging using an IntraVascular MRI (IVMRI) catheter specifically designed for the coronary arteries. This innovative catheter eliminates the need for expensive and cumbersome external MRI setups by miniaturizing essential MRI components to less than 2 millimeters in size. The advanced technology allows for precise imaging within the coronary arteries, revolutionizing the field of medical imaging and providing a more efficient and cost-effective solution for clinicians and patients alike.

VisionCare Ophthalmic Technologies

Series A in 1999
VisionCare Ophthalmic Technologies, Inc., established in 1997 and headquartered in Saratoga, California, is a specialty medical device company dedicated to improving vision for individuals with untreatable retinal disorders. The company focuses on the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices. Its flagship product, the Implantable Miniature Telescope (IMT), is an FDA-approved device designed to enhance vision in patients with end-stage age-related macular degeneration (AMD). The IMT is integral to the CentraSight treatment program, which guides patients through diagnosis, surgical evaluation, and postoperative care. VisionCare's mission is to restore visual functionality and improve quality of life for individuals with untreatable retinal disorders, primarily focusing on End-Stage AMD, the leading cause of blindness in older Americans.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.